PMID- 25540586
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141225
LR  - 20200929
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 10
DP  - 2014
TI  - Reduced serum brain-derived neurotrophic factor in patients with first onset 
      vitiligo.
PG  - 2361-7
LID - 10.2147/NDT.S74826 [doi]
AB  - PURPOSE: Vitiligo is an acquired pigmentary skin disease that can cause serious 
      cosmetic problems. There have been numerous and well established studies that 
      have demonstrated the comorbidity of various psychiatric disorders in patients 
      with vitiligo. However, to our knowledge, there have been no studies 
      investigating whether a psychiatric biomarker, such as brain-derived neurotrophic 
      factor (BDNF), is associated with vitiligo. PATIENTS AND METHODS: This study was 
      conducted in Namik Kemal University Medical Faculty, Departments of Dermatology 
      and Psychiatry between January 2013 and September 2014. After meeting inclusion 
      and exclusion criteria, serum BDNF levels were assayed in 57 patients with first 
      onset vitiligo and no known current or past psychiatric disorder and compared 
      with BDNF levels in 58 age and sex matched healthy subjects. RESULTS: The age and 
      female/male ratios were similar between groups. The mean values of serum BDNF 
      were 1.57+/-0.97 ng/dL and 2.37+/-1.73 ng/dL in the vitiligo group and in the healthy 
      control group, respectively. The mean BDNF level was significantly higher in the 
      healthy control group compared with the vitiligo group (t=2.76, P=0.007). 
      CONCLUSION: This is the first study to compare serum BDNF levels between patients 
      with vitiligo and healthy subjects. The reduced level of serum BDNF in patients 
      with vitiligo may be directly related to the etiology of vitiligo or associated 
      with the high percentage of psychiatric disorders in that patient population. 
      Further studies are needed to support our preliminary results.
FAU - Yanik, M Emin
AU  - Yanik ME
AD  - Department of Dermatology, Faculty of Medicine, Namik Kemal University, Tekirdag, 
      Turkey.
FAU - Erfan, Gamze
AU  - Erfan G
AD  - Department of Dermatology, Faculty of Medicine, Namik Kemal University, Tekirdag, 
      Turkey.
FAU - Albayrak, Yakup
AU  - Albayrak Y
AD  - Department of Psychiatry, Faculty of Medicine, Namik Kemal University, Tekirdag, 
      Turkey.
FAU - Aydin, Murat
AU  - Aydin M
AD  - Department of Biochemistry, Faculty of Medicine, Namik Kemal University, 
      Tekirdag, Turkey.
FAU - Kulac, Mustafa
AU  - Kulac M
AD  - Department of Dermatology, Faculty of Medicine, Namik Kemal University, Tekirdag, 
      Turkey.
FAU - Kuloglu, Murat
AU  - Kuloglu M
AD  - Department of Psychiatry, Faculty of Medicine, Akdeniz University, Antalya, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20141212
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4270357
OTO - NOTNLM
OT  - disease
OT  - neurotrophin
OT  - psychosomatic
OT  - skin
EDAT- 2014/12/30 06:00
MHDA- 2014/12/30 06:01
PMCR- 2014/12/12
CRDT- 2014/12/26 06:00
PHST- 2014/12/26 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2014/12/30 06:01 [medline]
PHST- 2014/12/12 00:00 [pmc-release]
AID - ndt-10-2361 [pii]
AID - 10.2147/NDT.S74826 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2014 Dec 12;10:2361-7. doi: 10.2147/NDT.S74826. 
      eCollection 2014.